Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06341660
Status:
RECRUITING
Last Update Posted:
2024-04-02
First Post:
2024-03-13
Brief Title:
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer NSCLC
Sponsor:
Guangzhou Institute of Respiratory Disease
Organization:
Guangzhou Institute of Respiratory Disease
Organization Data
Organization:
Guangzhou Institute of Respiratory Disease
Class:
OTHER
Study ID:
CROC202313
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Guangzhou Institute of Respiratory Disease
Lead Sponsor Class:
OTHER
Responsible Party:
Zhou Chengzhi
Responsible Party Title:
Director
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Guangzhou Institute of Respiratory Disease
Old Name:
None
Old Organization:
None